ICU Endocrine Issue CIRCI and Glycemic Control Paul Marik, MD, FCCM, FCCP Division of Pulmonary and CCM Thomas Jefferson University Philadelphia, PA.

Slides:



Advertisements
Similar presentations
Susan Alexander, DNP, CNS, CRNP, BC- ADM College of Nursing University of Alabama in Huntsville Clinical Affiliation: Outpatient Diabetes Self-Management.
Advertisements

In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
Endocrinology and Metabolism in Intensive care 馬偕醫院內分泌暨新陳代謝科 陳偉哲.
The golden hour(s) for severe sepsis and septic shock treatment
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
Adjunctive Pharmacotherapy In Sepsis นายแพทย์ เฉลิมไทย เอก ศิลป์ สถาบันสุขภาพเด็กแห่งชาติ มหาราชินี
Karyn L. Butler, MD, FACS, FCCM Chief, Surgical Critical Care
MODELING METHOD Glucose-Insulin System Model CLINICAL DATA DATA: Are taken from the SPRINT [3] TGC cohort totalling 393 patients and ~40,000 patient hours.
Sepsis Protocol Go Live December 1, 2009 Hendricks Regional Health.
Severe Sepsis Initial recognition and resuscitation
Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis/Septic Shock CR 杜宜霖.
Sepsis.
Early Goal Therapy in Severe Sepsis & Septic Shock
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Hypoglycemia Paolo Aquino 29 January Overview of hypoglycemia  What is it?  Why do we care about it?  What causes it?  How do we diagnose it?
Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock Dellinger RP, Levy MM, Rhodes A, Annane D, Carcillo JA, Gerlach H,
Adrenal Dysfunction following Cardiac Surgery
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.
Sarah Struthers, MD March 19, 2015
Mr PS 76 years old COPD, no DM Severe CAP Day 1- intubated, sedated, high o2 requirements, vasopressor dependent Starting early EN Glucose 11.1 mmol/L.
The Patient Undergoing Surgery: Proven Steps to Better Outcomes Ariel U. Spencer, MD Lafayette Surgical Clinic Lafayette, Indiana.
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.

Department of Anesthesiology and Critical Care Medicine Hadassah Medical Center Steroids: Benefits vs. Risks Risk/Benefit: Where are we now? Charles L.
Adrenal Insufficiency in ICU
Common Endocrine Issues in the Hospitalized Patient Jordan L. Geller, M.D. Attending Physician Cedars-Sinai Medical Center Division of Endocrinology Clinical.
Biosensors Data for Systems Analysis DuringConvalescence Palmer Q. Bessey, MD Burn Center Weill Medical College Biomedical Engineering Retreat Ithaca,
Insulin Therapy in the ICU:
CHEST. 2007;131(4): Methylprednisolone Infusion in Early Severe ARDS - Results of a Randomized Controlled Trial.
Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.
44 y/o female, Known case of Addison's disease, For elective cholecystectomy. How to optimize the patient’s state during the surgery?
Monthly Journal article review: Vimmi Kang PGY 2
SEPSIS & SEPTIC SHOCK Jaime Palomino, MD Pulmonary & Critical Care Medicine Tulane University Health Sciences Center New Orleans, Louisiana.
Shiva Sharma SHO Breast/Endocrine Surgery.  Introduction  Roles of Glutamine in the body  Tissue Protection  Anti-inflammatory regulation  Preservation.
EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.
Hyperglycemia: Is This Still a Concern? Lauren E. Healy BA, PharmD, BCPS NYSCHP Downstate Critical Care Program October 2, 2015.
Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCOCABG Trial.
Meduri et all Chest 2007;131; Background  Inflammation in the first week of MV determines resolving vs un-resolving  Un-resolving ARDS LIS by.
Early Enteral Nutrition in the Critically Ill. Objectives To define early enteral nutrition To review the benefits of early enteral nutrition To explain.
Copyright 2008 Society of Critical Care Medicine
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit The SAFE Study Investigators N Engl J Med 2004: 350:
Postoperative Glucose Control and SCIP Measures Gorav Ailawadi, MD Chief, Adult Cardiac Surgery University of Virginia April 25, 2015.
Achieving Glycemic Control in the Hospital Setting Part 1 of 3
Top Papers in Critical Care 2013 Janna Landsperger RN, MSN, ACNP-BC.
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Corticosteroid Therapy in Acute illness Uptodate ICU-Acquired Weakness and Recovery from Critical Illness, N Engl J Med 2014 Hydrocortisone.
Septic Shock Stuart Forman MD, FAAFP Contra Costa Regional Medical Center June 2009.
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Risk Factors and Outcome of Changes in Adrenal Response to ACTH in the Course of Critical Illness Margriet Fleur Charlotte de Jong, MD, PhD, Albertus Beishuizen,
Steroid Therapy.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
Giuseppe Bello, MD; Mariano Alberto Pennisi, MD; Luca Montini, MD Serena Silva, MD; Riccardo Maviglia, MD; Fabio Cavallaro, MD Chest 2009;135;
N Engl J Med 2010;362: R3 CHAE JUNGMIN/ Prof KIM MYENGGON.
Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult ICU patients Crit Care Med 2007 ; 35 :
경희대 호흡기내과 ACUTE RESPIRATORY DISTRESS SYNDROME (Update 2013) 호흡기내과 박명재.
Update in Critical Care Medicine Ann Intern Med 2007;147:
Sepsis-3 new definitions of sepsis and septic shock
Traitements non Antibiotiques du Choc Septique Djillali ANNANE, Hôpital Raymond Poincaré Garches,
Impact of Intensive Insulin Therapy on Neuromuscular Complications and Ventilator Dependency in the Medical Intensive Care Unit Greet Hermans, Alexander.
Acute Adrenal Insufficiency
Management of diabetes mellitus in hospitalized patients
Surgical ICU, Heart Institute University of São Paulo
Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock Dellinger RP, Levy MM, Rhodes A, Annane D, Carcillo JA, Gerlach.
Stress and Disease Chapter 8.
Relative Adrenal Insufficiency
Traditional parenteral antihypertensive treatment
Adrenal Insufficiency (AI) in the Septic Patient
Infections in Surgical Patients: Intensive Care Unit
Corticosteroids in the ICU
Presentation transcript:

ICU Endocrine Issue CIRCI and Glycemic Control Paul Marik, MD, FCCM, FCCP Division of Pulmonary and CCM Thomas Jefferson University Philadelphia, PA

Slide 3 Learning Objectives To understand the physiology of cortisol production in stress and critical illness. To review the recommendations for the diagnosis and management of corticosteroid insufficiency in the ICU. To understand the role of insulin and glucose regulation in stress hyperglycemia. To appreciate the effects of intensive insulin therapy.

Slide 4 The Stress Response Biologic, physical, or psychologic stressors generally precipitate similar response – “general adaptation syndrome” Selye H. A syndrome produced by diverse nocuous agents. Nature 1936;138:32

Slide 5 The HPA Axis

Slide 6 Cortisol & the Stress Response Fight & flight response –Glucose – fuel –Hemodynamic reserve Suppress activated defense mechanisms –Prevent tissue damage –Prevent excessive inflammation

Slide 7 Glucocorticoids Regulate gene transcription in every cell CHO-lipid-protein metabolism Immune function Cytokine synthesis and action Synthesis of catecholamines Synthesis of adrenergic receptors Cardiac contractility Vascular tone Membrane permeability Many other functions…..

Slide 8 Cortisol Synthesis in Sepsis TNFTNF Endotoxin TNFTNF

Slide 9 Corticosteroid Insufficiency - CIRCI Severe sepsis, septic shock, and ARDS are characterized by relative corticosteroid insufficiency with an exaggerated pro-inflammatory response. Pro-inflammatory mediators Anti-inflammatory mediators Homeostasis Cortisol NF-kB Immune dysregulation

Slide 10 CIRCI Adrenal insufficiency in critical illness is best described by the term critical illness-related corticosteroid insufficiency (CIRCI). The terms absolute or relative adrenal insufficiency are best avoided in the context of critical illness and should be replaced by the term CIRCI. CIRCI is a dynamic process, i.e., patients may not have CIRCI on admission to the hospital/ICU but may develop CIRCI during the course of the illness.

Slide 11 CIRCI CIRCI is defined as inappropriate corticosteroid activity for the severity of the patient’s illness. Relative cortisol insufficiency –Suppression at any point in the HPA axis with inadequate corticosteroid release –Drugs or destruction of components of the HPA axis by hemorrhage or necrosis Tissue resistance Analogous to Type II Diabetes

Slide 12 Adrenergic receptors Catecholamine NF- κ B Increased pro-inflammatory mediators CIRCI – Clinical Manifestations

Slide 13 Who to Treat? RCT demonstrating benefit from “moderate-dose” steroids –General ICU patients (n=1) –Septic shock (n=6) –Severe sepsis (n=2) –ALI/ARDS (n=5) –Ventilator weaning (n=1) –AF prophylaxis post-cardiac surgery (n=7) Cohort studies suggesting benefit from “moderate-dose” steroids –Liver failure (n=2) –Pancreatitis (n=1) RCT demonstrating NO benefit from “moderate-dose” steroids –CORTICUS (n=1)

Slide 14 Indications for steroids ?? ARDS –Progressive disease after 48 hours management –PaO2/FiO2 < 150 Septic shock: – Norepi > ug/kg/min within 12 hours of onset Cirrhosis/liver failure Prevent post-extubation stridor –-ve cuff leak test CABG Failure to wean? Pancreatitis? Head injury/SAH?

Slide 15 The clinical benefit of corticosteroids depends upon the dose, the duration of therapy, and weaning strategy* *Old Chinese proverb

Slide 16 Dosing Strategy The dose of glucocorticoid should be sufficient to down-regulate the pro-inflammatory response without causing immune-paresis and interfering with wound healing. The duration of glucocorticoid therapy should be guided by the duration of CIRCI and the associated duration of systemic inflammation. Myopathy and an increased risk of superinfections are more common in patients receiving in excess of 350 mg hydrocortisone equivalents per day. While suppressing an exaggerated pro-inflammatory response, a dose of mg hydrocortisone/day maintains helper T-cell responsiveness and innate immunity.

Slide 17 Crit Care Med. 2008;36:

Slide 18 Recommendations Dysfunction of the HPA axis in critical illness is best described by the term critical illness-related corticosteroid insufficiency (CIRCI). The terms absolute and relative adrenal insufficiency are best avoided in the context of critical illness. At this time, adrenal insufficiency in critical illness is best diagnosed by a delta cortisol (after 250 ug cosyntropin) of <9 ug/dL or a random total cortisol of <10 ug/dL. (2B) The use of free cortisol measurements cannot be recommended for routine use at this time. Although the free cortisol assay has advantages over the total serum cortisol, this test is not readily available. Furthermore, the normal range of the free cortisol in critically ill patients is currently unclear. (2B)

Slide 19 Recommendations The ACTH stimulation test should not be used to identify those patients with septic shock or ARDS who should receive GCs. (2B) Hydrocortisone should be considered in the management strategy of patients with septic shock, particularly those patients who have responded poorly to fluid resuscitation and vasopressor agents. (2B) Moderate-dose GC should be considered in the management strategy of patients with early severe ARDS (PaO2/FiO2 <200) and before day 14 in patients with unresolving ARDS. The role of GC in acute lung injury and less severe ARDS is less clear. (2B)

Slide 20 Recommendations In patients with septic shock, intravenous hydrocortisone should be given in a dose of 200 mg/day in four divided doses or as a continuous infusion at 10 mg/hour (240 mg/day). The optimal dosing regimen in patients with early severe ARDS is 1 mg/kg/day methylprednisolone as a continuous infusion. (1B) The optimal duration of GC treatment in patients with septic and early ARDS is unclear. However, based on published studies and pathological data, patients with septic shock should be treated for ≥7days before tapering, assuming there is no recurrence or signs of sepsis or shock. Patients with early ARDS should be treated for ≥14 days before tapering. (2B)

Slide 21 Recommendations GC treatment should be tapered slowly and not stopped abruptly. (2B) Treatment with fludrocortisone (50 ug orally once daily) is considered optional. (2B) Dexamethasone is not recommended for treatment of septic shock or ARDS.

Stress Hyperglycemia Role of Intensive Insulin Therapy

Slide 23 The Stress Response Cortisol Epinephrine Norepinephrine Glucagon Growth Hormone Prolactin Gluconeogenesis + Glycolysis = Stress Hyperglycemia

Slide 24 Stress Hyperglycemia Definition –Blood glucose >200 mg/dL (15%-20%) –Blood glucose >110 mg/dL (75%-97%) Etiology –Increased release of counter-regulatory hormones –Increased hepatic gluconeogenesis –Decreased insulin release –Insulin resistance

Slide 25 Hyperglycemia and Insulin  ROS, NADPH oxidase  TNF, IL-8,IL-6  TF, PAI-1 CATABOLIC  ROS, NADPH oxidase  TNF, IL-6  TF, PAI-1  NO synthase ANABOLIC Glucose Pro-inflammatory Insulin Anti-inflammatory

Slide 26 Insulin-Mediated Glucose Uptake: Muscle and Adipose Tissue

Slide 27 Once Upon a Time… by Greet Van den Berghe

Slide 28 Intensive Insulin Therapy Prospective unblinded RCT of 1,538 adult SICU patients –70% cardiothoracic Conventional –titrate glucose to mg/dL Intensive – titrate glucose to mg/dL Primary outcome –in-hospital mortality Secondary outcome –ICU mortality, days to weaning from MV, ICU and hospital LOS, new kidney injury, incidence of bacteremia Van den Berghe G et al. N Engl J Med. 2001;345:

Slide 29 Intensive Insulin Therapy Van den Berghe G et al. N Engl J Med. 2001;345:

Slide 30 Intensive Insulin Therapy in Critically Ill Patients ↓ Bloodstream infections by 46% ↓ ARF requiring dialysis or CRRT by 41% ↓ Critical illness polyneuropathy by 44% ↓ RBC transfusions by 50% Greater number of ventilator-free days Shorter ICU LOS Episodes of hypoglycemia (<40 mg/dL) –5.1% (IIT) vs. 0.8% (conventional) p <0.001 –No adverse consequences Van den Berghe G et al. N Engl J Med. 2001;345:

Slide 31 Van den Berghe G et al. Crit Care Med. 2003;31: ▲ BG > 150 mg/dL ● BG mg/dL ■ BG < 110 mg/dL Outcome of Intensive Insulin Therapy

Slide 32 Mechanisms of Reduced Morbidity and Mortality with Insulin Lower glucose –Improved macrophage/monocyte function –Decreased superoxide function and improved mitochondrial function (liver, neurons) Higher insulin –Anti-inflammatory effects –Anabolic effects –Improved lipid levels –Improved endothelial function Van den Berghe G. J Clin Invest. 2004;114:

Slide 33 Insulin Improves Dyslipidemia Abnormal serum lipid profiles in critically ill –↑ triglyceride levels, ↓↓ HDL and LDL. IIT results in almost complete reversal of hypertriglyceridemia, ↑ HDL and LDL. Lipid effects may explain beneficial effect on mortality and organ failure in prolonged critical illness. Mesotten D et al. J Clin Endocrinol Metab. 2004;89:

Slide 34 Intensive Insulin Therapy and Outcome in ICU Practice 1,600 mixed ICU patients at Stamford Hospital, CT, “before and after” design –800 on conventional therapy –800 IIT (BG <140 mg/dL) Less strict glucose control employed to avoid inadvertent hypoglycemia ~ BG 131 mg/dL in IIT vs. 152 mg/dL in conventional Krinsley JS. Mayo Clin Proc. 2004;79:

Slide 35 The Fairy Tale Continues…..

Slide 36 Intensive Insulin Therapy Prospective unblinded RCT of 1,200 adult MICU patients staying >3 days Conventional –titrate glucose to mg/dL Intensive –titrate glucose to mg/dL Primary outcome –in-hospital mortality Secondary outcome –ICU mortality, days to weaning from MV, ICU and Hospital LOS, new kidney injury, incidence of bacteremia Van den Berghe G et al. N Engl J Med. 2006;354:

Slide 37 Intensive Insulin Therapy Van den Berghe G et al. N Engl J Med. 2006;354:

Slide 38 Intensive Insulin Therapy Van den Berghe G et al. N Engl J Med. 2006;354: % calories by parenteral nutrition

Slide 39 Intensive Insulin Therapy IIT – 18.7% hypoglycemia Van den Berghe G et al. N Engl J Med. 2006;354:

Slide 40 Intensive Insulin Therapy ConventionalIntensive Hospital Mortality - ITT40%37.3% Hypoglycemia - ITT3.1%18.7% Hospital Mortality - hypoglycemia 73.3%61.9% Mortality at day 32.8%3.9% Van den Berghe G et al. N Engl J Med. 2006;354: Hypoglycemia increases risk of DEATH

Intensive Insulin Therapy Clinical Trials: Update

Slide 42 German Competence Network Sepsis (SepNet) Prospective, randomized, multicenter study of intensive vs. conventional insulin therapy on outcome in patients with severe sepsis/septic shock April December patients (planned 600): –247 intensive insulin (80­110 mg/dL) –241 conventional (180­200 mg/dL) N Engl J Med. 2008;358:

Slide 43 VISEP Trial: Stopped in Late 2005 Conventional n= 241 Intensive Insulin n=247 Male61.9%49.8% Mean age, year64.9%63.8% Hypoglycemia4.1%17* Serious adverse events5.2%10.9%# 28-day mortality26%24.7% 90-day mortality35.4%39.7% * p=<0.001; # p<0.01

Slide 44 GLUCONTROL Prospective, multicenter RCT of adult patients 7 countries, 21 ICUs in 19 centers Intervention: –Intensive: titrate glucose to mg/dL –Conventional: titrate glucose to mg/dL Planning: –3,500 patients required to detect 4% ↓ in mortality –Interim analysis each 100 ICU deaths Study stopped on May 29, 2006 –Safety concern

Slide 45 GLUCONTROL Group A n=538 (IIT) Group B n=553 (CV) p value Mortality rate12.27%9.76%0.186 Death among patients with hypoglycemia (<40 mg/dL) 18.3%11.6%0.0002

Slide 46 Ann Intern Med. 2007;146:

Slide 47 Intensive Intraoperative Insulin Rx Ann Intern Med. 2007; 146:

Slide 48 Tight Glycemic Control – Unanswered Questions Ideal goal? – mg/dL – mg/dL – mg/dL Elective surgical (cardiac) vs. medical Only in patients on TPN? Less tight first 3 days? How to measure blood glucose? –Accuracy of “Accuchecks” –Q12 simultaneous lab glucose measurements

Case Studies with Questions The following are case studies that can be used for review of this presentation. Review Cases Skip Case Studies

Slide 50 Case Presentation A 56-year-old gentleman status post-coronary artery bypass surgery develops a ventilator-associated pneumonia with bacteremia. Despite fluid resuscitation, he remains hemodynamically unstable. His urine output has decreased. He is currently receiving 20 μg/min of norepinephrine, 2.4 units/hour of vasopressin, and 5 μg/min of dobutamine.

Slide 51 Case Presentation His vital signs are notable for: –A CVP of 12 –BP of 90/30 mm Hg –SpO2 of 91% on an FIO2 of 80% –Temperature of 40 degrees Celsius His laboratory data are notable for: –WBC: 17,000/mm3 –Random cortisol: 9 μg/dL –Glucose: 217 mg/dL

Slide 53 Conclusion This concludes this presentation.